阿法骨化醇治疗早期糖尿病肾病的临床研究

Clinical Study on the Treatment of Early Diabetic Nephropathy with Alfacalcidol

目的探讨阿法骨化醇治疗早期糖尿病肾病(DN)的临床效果。方法方便选取2018年1月2019年2月东莞厚街医院的60例微量蛋白尿(MAU)患者作为研究对象,随机分为对照组(n=30)与治疗组(n=30),对照组采用常规方式治疗,治疗组施以阿法骨化醇治疗,观察观察两组治疗前及治疗2个月后的FBG、HbAIC、INS、25 (OH)VD、UAER、Scr、等指标值的变化情况以及血浆肾素活性、血管紧张素Ⅱ水平比较。结果治疗前,两组的上述指标,差异无统计学意义(P>0.05);治疗2个月后,治疗组的FBG、HbA1C、UAER、Scr、TG、LDL-C、ISI等指标值明显降低,INS、25(OH)VD、HOMA2IR、HDL-C等指标值明显升高,与对照组相比,差异有统计学意义(P<0.05);治疗组治疗前、治疗2个月后血浆肾素活性分别为(122.39±8.24)pg/mL、(92.17±7.15)pg/mL,血管紧张素Ⅱ分别为(150.53±9.17)pg/mL、(112.68±5.03)pg/mL,均明显高于对照组,差异有统计学意义(t=40.662、28.935,41.192、30.815,P<0.05)。结论阿法骨化醇治疗早期糖尿病肾病具有良好的临床效果。

Objective To investigate the clinical effect of Alfacalcidol in the treatment of early diabetic nephropathy(DN).Methods 60 patients with microalbuminuria(MAU) from Houjie Hospital in Dongguan from January 2018 to February 2019 were convenienty divided into control group(n=30) and treatment group(n=30).In the conventional way,the treatment group was treated with Alfacalcidol,and the changes of FBG,HbA1 C,INS,25(OH)VD,UAER,Scr,etc.before and after treatment were observed.And comparison of plasma renin activity and angiotensin II levels.Results After 2 months of treatment,the indicators in the treatment group were significantly different from the control group,the difference was statistically significant(P<0.05).The plasma renin activity of the treatment group before treatment and after 2 months of treatment was(122.39±8.24)pg/mL,(92.17±7.15)pg/mL,angiotensin II(150.53±9.17)pg/mL,(112.68±5.03)pg/mL,respectively,were significantly higher than the control group,the difference was statistically significant(t=40.662,28.935,41.192,30.815,P<0.05).Conclusion Alfacalcidol has a good clinical effect in the treatment of early diabetic nephropathy,which not only improves insulin resistance,but also reduces urine protein.